Compare PICS & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PICS | SLBT |
|---|---|---|
| Founded | 2012 | N/A |
| Country | Brazil | Taiwan |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2021 | 2025 |
| Metric | PICS | SLBT |
|---|---|---|
| Price | $10.19 | $2.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | ★ 538.1K | 50.5K |
| Earning Date | 05-30-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.65 | N/A |
| Revenue Next Year | $39.85 | N/A |
| P/E Ratio | $29.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.32 | $2.51 |
| 52 Week High | $18.49 | $6.25 |
| Indicator | PICS | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 42.19 |
| Support Level | $9.85 | $2.54 |
| Resistance Level | $11.50 | $2.89 |
| Average True Range (ATR) | 0.78 | 0.14 |
| MACD | -0.10 | 0.05 |
| Stochastic Oscillator | 10.27 | 42.11 |
PicS NV is a digital payments company. The company operates a peer-to-peer (P2P) transfer platform that enables individuals to send money via mobile devices. It provides digital wallets, instant payments (Pix), P2P transfers, credit cards, loans, investments, insurance, and SMB payment solutions. The company has four reportable segments: Consumer Banking, Small and Medium-Sized Businesses, Audiences and Ecosystem Integration, and Institutional. The majority of the company's revenue is derived from the Consumer Banking segment, which generates revenue from various transaction activities occurring in the digital wallet, such as Pix, peer-to-peer (P2P) transfers, and bill payments.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.